Description:

Cardiology Grand Rounds
Monday, April 28th, 2014 at 7:30am
Pritzker Auditorium (Feinberg, 3rd Floor)

New Anticoagulants for Non-Valvular Atrial Fibrillation: Integrating New Evidence into Clinical Practice

Speaker
Sanjay Kaul, MD, MPH
Director, Vascular Physiology and Thrombosis Research
Laboratory at the Burns and Allen Research Institute
Cedars-Sinai Medical Center

Course Director
Clyde W. Yancy, MD, MSc
Chief, Division of Cardiology
Northwestern University Feinberg School of Medicine

(Please remember to sign in)
**No food or drink allowed in Pritzker Auditorium**
________________________________________
Disclosure Information
Dr. Kaul is a consultant with Boehringer Ingelheim and the FDA/CDER.  In addition, he holds equity in Johnson & Johnson.  For the planning committee members of this activity, Dr. Hossein Ardehali, Dr. Donald Lloyd-Jones, Dr. Sanjiv Shah, and Michael Yensel have nothing to disclose.

FSM’s CME Leadership and Staff listed have nothing to disclose:
John X. Thomas, Jr., PhD, Sr. Associate Dean for Medical Education, Genevieve Napier, CME Director, CME Project Specialists, Jen Banys & Tara Scavelli.

Objectives
At the conclusion of this activity, participants should be able to:

1. Summarize evidentiary landscape for New Oral Anticoagulants (NOACs) for Non-Valvular Atrial Fibrillation (NVAF).
2. Discuss integrating trial evidence into clinical practice.
3. Review guideline recommendations for NOACs in NVAF.

Accreditation Statement
The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.